Compare SHC & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHC | PTCT |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 5.5B |
| IPO Year | 2020 | 2006 |
| Metric | SHC | PTCT |
|---|---|---|
| Price | $17.91 | $59.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 15 |
| Target Price | $22.61 | ★ $100.33 |
| AVG Volume (30 Days) | ★ 1.8M | 1.2M |
| Earning Date | 11-03-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 68.75 | ★ 264.48 |
| EPS | 0.28 | ★ 0.90 |
| Revenue | ★ $1,163,617,000.00 | $264,734,000.00 |
| Revenue This Year | $7.16 | N/A |
| Revenue Next Year | $5.91 | $9.47 |
| P/E Ratio | ★ $64.59 | $67.73 |
| Revenue Growth | 5.74 | ★ 36.19 |
| 52 Week Low | $13.09 | $58.80 |
| 52 Week High | $19.85 | $90.87 |
| Indicator | SHC | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 42.82 | 34.70 |
| Support Level | $16.74 | N/A |
| Resistance Level | $18.77 | $68.93 |
| Average True Range (ATR) | 0.49 | 1.93 |
| MACD | -0.03 | -0.15 |
| Stochastic Oscillator | 24.83 | 13.82 |
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.